Low molecular weight heparins: Are they superior to unfractionated heparins to prevent and to treat deep vein thrombosis?

Thrombosis Research

Volumn 100, Issue 2, 2000, Pages 113-120

  Boneu, Bernard ^a  

^a CHU RANGUEIL   (France)

Author keywords

Deep vein thrombosis; Low molecular weight heparin; Unfractionated heparin

Indexed keywords

ARDEPARIN; BLOOD CLOTTING FACTOR 10A INHIBITOR; CERTOPARIN; DALTEPARIN; ENOXAPARIN; HEPARIN; LOW MOLECULAR WEIGHT HEPARIN; NADROPARIN; PARNAPARIN; REVIPARIN; THROMBIN INHIBITOR; TINZAPARIN;

ANTICOAGULANT THERAPY; ANTICOAGULATION; BLEEDING; CLINICAL TRIAL; DEEP VEIN THROMBOSIS; DOSE RESPONSE; DRUG ACCUMULATION; DRUG EFFICACY; DRUG MECHANISM; DRUG SAFETY; ENZYME INHIBITION; HUMAN; IMMUNOGENICITY; KIDNEY FAILURE; MOLECULAR WEIGHT; OSTEOPOROSIS; PARTIAL THROMBOPLASTIN TIME; PRIORITY JOURNAL; REVIEW; THROMBOCYTOPENIA; TREATMENT OUTCOME;

EID: 0034667831     PISSN: 00493848     EISSN: None     Source Type: Journal    
DOI: 10.1016/s0049-3848(00)00331-5     Document Type: Review

References (41)

1. Heparin
2. Heparin and low-molecular-weight heparin. Mechanisms of action, pharmacokinetics, dosing considerations, monitoring, efficacy and safety
3. Role of ternary complexes in which heparin binds both antithrombin and proteinase, in the acceleration of the reactions between antithrombin and thrombin or factor Xa
4. Mechanisms for inhibition of the generation of thrombin activity by sulfated polysaccharides
5. Unfractionated heparin inhibits thrombin-catalyzed amplification reactions of coagulation more efficiently than those catalyzed by factor Xa
6. Adjusted versus fixed doses of the low-molecular-weight heparin Fragmin® in the treatment of deep vein thrombosis
7. Markers of hemostatic system activation in acute deep venous thrombosis-evolution during the first days of heparin treatment
8. Aging and venous thromboembolism influence the pharmacodynamics of the anti-factor Xa and anti-thrombin activities of a low molecular weight heparin (Nadroparin)
9. Comparison of two low-molecular-weight heparins for the prevention of postoperative venous thromboembolism after elective hip surgery
10. Occurrence of thrombosis and haemorrhage, relationship with anti-Xa, anti-IIa activities, and D-dimer plasma levels in patients receiving a low molecular weight heparin, enoxaparin or tinzaparin, to prevent deep vein thrombosis after hip surgery
11. Unfractionated heparin and CY216: Pharmacokinetics and bioavailabilities of the anti-factor Xa and IIa: Effects of intravenous and subcutaneous injection in rabbits
12. Pharmacokinetic studies of standard UFH, and low molecular weight heparins in the rabbit
13. Disappearance of circulating anti-Xa activity after intravenous injection of standard heparin and of low molecular weight heparin (CY216) in normal and nephrectomized rabbits
14. Pharmacokinetics of heparin and low molecular weight heparin fragment (Fragmin) in rabbits with impaired renal or metabolic clearance
15. A comparison of low-molecular-weight heparin administered primarily at home with unfractionated heparin administered in the hospital for proximal deep-vein thrombosis
16. Treatment of venous thrombosis with intravenous unfractionated heparin administered in the hospital as compared with subcutaneous low-molecular-weight heparin administered at home
17. Low molecular weight heparin therapy: Is monitoring needed?
18. The relationship between the hemorrhagic and antithrombotic properties of low molecular weight heparin in rabbits
19. Bleeding times in rats treated with heparin, heparin fragments of high and low anticoagulant activity and chemically modified heparin fragments of low anticoagulant activity
20. Does low molecular weight heparin cause less bleeding?
21. Low molecular weight heparin (Kabi 2165) as thromboprophylaxis in elective visceral surgery. A randomized, double-blind study versus unfractionated heparin
22. Low molecular weight heparin in prevention of perioperative thrombosis
23. Efficacy and safety of low molecular weight heparin and standard unfractionated heparin for prophylactic of postoperative venous thromboembolism: European multicenter trial
24. Randomized trial of subcutaneous low molecular weight heparin. CY216 (Fraxiparine) compared with intravenous unfractionated heparin in the curative treatment of submassive pulmonary embolism: A dose ranging study
25. Comparison of efficacy and safety of low molecular weight heparins and unfractionated heparin in initial treatment of deep venous thrombosis: A meta-analysis
26. Treatment of deep venous thrombosis with low-molecular-weight heparins
27. Low molecular weight heparins (LMWH) in the treatment of patients with acute venous thromboembolism
28. Low-molecular-weight heparins compared with unfractionated heparin for treatment of acute deep venous thrombosis
29. Subcutaneous low molecular weight heparin compared with continuous intravenous heparin in the treatment of proximal deep vein thrombosis
30. Heparin-induced thrombocytopenia: Towards consensus
31. Heparin-induced thrombocytopenia in patients treated with low-molecular-weight heparin or unfractionated heparin
32. Anticoagulant activities of heparin oligosaccharides and their neutralization by platelet factor 4
33. Heparin osteoporosis
34. Heparin-induced osteoporosis in rats
35. Effects of low molecular weight heparin and unfragmented heparin on induction of osteoporosis in rats
36. Comparison of subcutaneous unfractionated heparin with a low molecular weight heparin (Fragmin®) in patients with venous thromboembolism and contraindications to Coumarin
37. Safety of low-molecular-weight heparin in pregnancy: A systematic review
38. Low-molecular-weight heparin versus standard heparin in general and orthoaedic surgery: A meta-analysis
39. Effectiveness and safety of low molecular weight heparins (LMWH) in the prevention of venous thromboembolism (VTE)
40. Low molecular weight heparin versus standard heparin for prevention of venous thromboembolism after major abdominal surgery